Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Begbies Traynor makes 'good start' to new trading year

(Sharecast News) - Corporate restructuring specialist Begbies Traynor said on Thursday that it had delivered a tenth consecutive year of profitable growth, with full-year results ahead of original market consensus expectations. Begbies Traynor, which will hold its annual general meeting today, said it had seen strong organic growth across both of its divisions, supporting a marked increase in free cash flow and an 8% hike to its total dividend - its eighth consecutive year of dividend growth.

The London-listed firm stated that its strategy of investing in organic development and earnings-enhancing M&A had created a diversified and resilient platform, with the business tripling in size over the past decade and adjusted pre-tax profits rising sixfold. It added that progress towards its medium-term revenue target of £200m had continued.

Looking ahead, Begbies said it had made a good start to the new financial year, with encouraging activity levels and positive momentum across the group. Begbies also noted that recent recruitment of senior fee earners was expected to support growth in the second half and beyond.

Results for the three months ended 31 July were in line with expectations, with the group stating that it remained confident of meeting FY market forecasts for revenues of £163m to £164m and adjusted pre-tax profits of £23.7m to £24.9m.

As of 0940 BST, Begbies Traynor shares were down 0.84% at 120.98p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.